Skip to Content
You are currently on the new version of our website. Access the old version .
TargetsTargets
  • Review
  • Open Access

7 September 2024

13 Pages

Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations

,
,
,
and
1
Department of Pulmonary Oncology, AORN dei Colli Monaldi, 80131 Naples, Italy
2
Department of Precision Medicine, Università degli Studi della Campania “Luigi Vanvitelli”, 80131 Naples, Italy
3
U.O.C. Organizzazione e Programmazione dei Servizi Sanitari, AORN dei Colli Monaldi, 80131 Naples, Italy
4
Division of Medical Oncology, “ULSS 15 Cittadella”, 35131 Padova, Italy

Abstract

The vast majority of advanced NSCLC cases are histologically represented by adenocarcinomas. EGFR activating mutations (exon 19 deletions, exon 21 L858R substitutions, exon 20 insertions) represent one of the most common druggable alterations. Since erlotinib’s FDA approval in 2013, EGFR-TKIs have represented a staple of EGFR+ advanced NSCLC treatment, with osimertinib representing the latest major FDA-approved third-generation EGFR-TKI. In recent years, however, several preclinical data have highlighted promising results regarding combination therapies involving EGFR-TKIs plus chemotherapy, and various recent clinical trials have confirmed these results. In addition, in 2021, amivantamab was the first FDA-approved mAb for the treatment of EGFR+ advanced NSCLC patients; according to some extremely up-to-date clinical trials, the combination of amivantamab plus chemotherapy is also associated with superior results. Therefore, this paper aims to provide a comprehensive review of both the bases and the latest evidence of the combination therapies involving EGFR+ advanced NSCLC patients.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.